The epitope recognized by PLA0184 maps to a region between residue 1 and 50 of human poly (ADP-ribose) polymerase family, member 1 using the numbering given in entry NP_001609.1 (GeneID 142).
PARP1 (Poly-ADP-ribose polymerase 1) is a member of PARP family of enzymes that transfer the ADP-D-ribosyl group of NAD(+) to an acceptor carboxyl group on proteins. PARP1 catalyzes the poly-ADP-ribosylation of histone and non-histone proteins in response to DNA damage. The over-activation of PARP-1 in response to DNA damage has been shown to promote cell and tissue injury. This observation has initiated research into the therapeutic potential of PARP1 inhibitors in the treatment of cancer, cardiovascular disease, and brain injury.
免责声明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Neonatal microcephaly and adult Guillain-Barré syndrome are severe complications of Zika virus (ZIKV) infection. The robustly induced inflammatory cytokine expressions in ZIKV-infected patients may constitute a hallmark for severe disease. In the present study, the potential role of high mobility
Molecular cancer research : MCR, 20(12), 1799-1810 (2022-09-09)
The TP53 gene is mutated in 80% of triple-negative breast cancers. Cells that harbor the hot-spot p53 gene mutation R273H produce an oncogenic mutant p53 (mtp53) that enhances cell proliferative and metastatic properties. The enhanced activities of mtp53 are collectively